Moneycontrol
HomeNewsOpinionIndian pharma will benefit if a new US bill is passed

Indian pharma will benefit if a new US bill is passed

Sundeep Khanna   •

A proposed legislation could make it difficult for brand-name companies to delay the launch of generics and biosimilars

The only solution to consolidated buying power is for suppliers to refrain from selling at cutthroat rates, given the number of Indian pharma firms ready to supply at any price point. (Representative image)

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts